9 Genomic Testing Turnaround Times in Non-Small Cell Lung Cancer: A Regional Service Review

IF 5.3 2区医学 Q1 ONCOLOGY Lung Cancer Pub Date : 2026-02-01 Epub Date: 2026-02-27 DOI:10.1016/j.lungcan.2026.108958

Emily Scott , Sarah Bodsworth , Jo Lowry , Emmanuel Ncube , Richard Sandford , Peter J Hoskin

引用次数: 0

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

非小细胞肺癌基因组检测周转时间：区域服务回顾

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Lung Cancer 医学-呼吸系统

CiteScore

9.40

自引率

3.80%

发文量

407

审稿时长

25 days

期刊介绍： Lung Cancer is an international publication covering the clinical, translational and basic science of malignancies of the lung and chest region.Original research articles, early reports, review articles, editorials and correspondence covering the prevention, epidemiology and etiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined treatment modalities, other treatment modalities and outcomes of lung cancer are welcome.

期刊最新文献

Efficacy and safety of adjuvant ensartinib in stage I ALK-positive NSCLC patients: a retrospective, multicenter study Artificial intelligence–based assessment of tumor bed stroma in non–small cell lung cancer after neoadjuvant therapy: Association with pathologic response and survival. A multicenter study Subtyping limited stage small cell lung cancer (LS SCLC) reveals inflammatory subtypes with improved chemoradiotherapy outcomes The management of complex patients with inoperable stage III NSCLC: practical lessons from case-based discussion Corrigendum to “The safety of extended dosing pembrolizumab when compared to traditional dosing: a review and meta-analysis of retrospective studies” [Lung Cancer 204 (2025) 108585]